Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects
Potential Xarelto Successor Prioritized
Executive Summary
Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.
You may also be interested in...
Anthos Changing Course With Factor XIa Inhibitor, Targeting Atrial Fibrillation Patients First
With a Phase II study stopped for efficacy in bleeding reduction, Anthos hopes to bring abelacimab, a dual Factor XI/XIa inhibitor to market to prevent strokes in a-fib patients and to treat cancer patients with thrombosis.
High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data
BMS/Janssen’s milvexian and Bayer’s asundexian prevented strokes without major increases in severe bleeding and no fatal bleeds but Phase III outcomes are uncertain based on mixed Phase II data.